Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

534 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
GLP-1R agonist therapy for diabetes: benefits and potential risks.
Samson SL, Garber A. Samson SL, et al. Among authors: garber a. Curr Opin Endocrinol Diabetes Obes. 2013 Apr;20(2):87-97. doi: 10.1097/MED.0b013e32835edb32. Curr Opin Endocrinol Diabetes Obes. 2013. PMID: 23403741 Review.
However, the extremely low incidence of these events means further investigations are required before a causal link can be eliminated. ...SUMMARY: GLP-1R agonists offer sustained glycemic efficacy, weight loss benefits, and a low risk of hypoglycemia. The results of …
However, the extremely low incidence of these events means further investigations are required before a causal link can be eliminated …
Type 2 diabetes and cardiovascular risk factors.
Sharma MD, Farmer JA, Garber A. Sharma MD, et al. Among authors: garber a. Curr Med Res Opin. 2011 Nov;27 Suppl 3:1-5. doi: 10.1185/03007995.2011.620083. Curr Med Res Opin. 2011. PMID: 22106974
There is a lack of adequate evidence that improvement in glycemic control decreases CV risk....
There is a lack of adequate evidence that improvement in glycemic control decreases CV risk....
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group. Garber A, et al. Lancet. 2009 Feb 7;373(9662):473-81. doi: 10.1016/S0140-6736(08)61246-5. Epub 2008 Sep 24. Lancet. 2009. PMID: 18819705 Clinical Trial.
METHODS: In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks. ...
METHODS: In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly …
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group. Raskin P, et al. Among authors: garber a. Diabetes Care. 2005 Feb;28(2):260-5. doi: 10.2337/diacare.28.2.260. Diabetes Care. 2005. PMID: 15677776 Clinical Trial.
RESULTS: A total of 209 subjects completed the study. At study end, the mean HbA(1c) value was lower in the BIAsp 70/30 group than in the glargine group (6.91 +/- 1.17 vs. 7.41 +/- 1.24%, P < 0.01). ...
RESULTS: A total of 209 subjects completed the study. At study end, the mean HbA(1c) value was lower in the BIAsp 70/30 group than in …
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, Holst J, Nauck M. Buse JB, et al. Among authors: garber a. J Clin Endocrinol Metab. 2011 Jun;96(6):1695-702. doi: 10.1210/jc.2010-2822. Epub 2011 Mar 30. J Clin Endocrinol Metab. 2011. PMID: 21450987 Clinical Trial.
Change in glycosylated hemoglobin A(1c) (HbA(1c)) by antibody status and magnitude [negative, positive (high or low level)]. ...After switching from exenatide to liraglutide, anti-exenatide antibodies did not compromise a further glycemic response to liraglutide (ad …
Change in glycosylated hemoglobin A(1c) (HbA(1c)) by antibody status and magnitude [negative, positive (high or low level)]. ...After …
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Garber A, et al. Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x. Diabetes Obes Metab. 2011. PMID: 21205128 Free PMC article. Clinical Trial.
CONCLUSION: Liraglutide monotherapy for 2 years provides significant and sustained improvements in glycaemic control and body weight compared with glimepiride monotherapy, at a lower risk of hypoglycaemia....
CONCLUSION: Liraglutide monotherapy for 2 years provides significant and sustained improvements in glycaemic control and body weight compare …
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group. Bode BW, et al. Among authors: garber a. Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. Diabetes Obes Metab. 2010. PMID: 20590735 Free PMC article. Clinical Trial.
METHODS: Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245). ...
METHODS: Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52- …
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ. Ray JA, et al. Among authors: garber a. Diabetes Obes Metab. 2007 Jan;9(1):103-13. doi: 10.1111/j.1463-1326.2006.00581.x. Diabetes Obes Metab. 2007. PMID: 17199725 Clinical Trial.
METHODS: Baseline patient characteristics and treatment effect data from the recent 'INITIATE' clinical trial served as input to a peer-reviewed, validated Markov/Monte-Carlo simulation model. ...Total lifetime costs were compared to efficacy rates in both arms as a
METHODS: Baseline patient characteristics and treatment effect data from the recent 'INITIATE' clinical trial served as input to a pe …
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Rosenstock J, et al. Among authors: garber a. Diabetes Obes Metab. 2006 Nov;8(6):650-60. doi: 10.1111/j.1463-1326.2006.00659.x. Diabetes Obes Metab. 2006. PMID: 17026489 Clinical Trial.
RSG/MET was initiated with a total daily dose of 2 mg/500 mg and could be increased up to 8 mg/2000 mg; MET therapy began with a total daily dose of 500 mg and could be increased up to 2000 mg; and RSG treatment began with a total daily dose of 4 mg and could …
RSG/MET was initiated with a total daily dose of 2 mg/500 mg and could be increased up to 8 mg/2000 mg; MET therapy began with a
Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
Rosenstock J, Rood J, Cobitz A, Huang C, Garber A. Rosenstock J, et al. Among authors: garber a. Diabetes Obes Metab. 2006 Nov;8(6):643-9. doi: 10.1111/j.1463-1326.2006.00648.x. Diabetes Obes Metab. 2006. PMID: 17026488 Clinical Trial.
Patients were assessed for efficacy and safety at five visits over a 24-week period. The primary efficacy end point was change from baseline in A1c at week 24. ...A clinically significant reduction in FPG (5.2 mmol/l) was observed after 4 weeks of treatment with RSG …
Patients were assessed for efficacy and safety at five visits over a 24-week period. The primary efficacy end point was change from b …
534 results
Jump to page
Feedback